Showing 1,101 - 1,120 results of 21,342 for search '(( significant genes decrease ) OR ( ((significant decrease) OR (significant increase)) decrease ))', query time: 0.73s Refine Results
  1. 1101

    Loss of MALS-1 function suppresses the mitochondrial and axon degeneration phenotypes that are caused by loss of RBM-26 function. by Tamjid A. Chowdhury (14149846)

    Published 2024
    “…(D) Loss of RBM-26 protein expression causes a decrease in mitoribosome expression, which was assayed with the MitoRibo-Tag system consisting of the MRPL-58 mitoribosomal protein tagged at its C-terminus with 3XFLAG (MRPL-58::3XFLAG). …”
  2. 1102
  3. 1103

    Overexpression of MALS-1 reduces mitochondria in the PLM axon and causes axon degeneration and axon overlap defects. by Tamjid A. Chowdhury (14149846)

    Published 2024
    “…(E) PLM axon beading phenotype caused by MALS-1 overexpression. (F) Decrease in mitochondria density (number of mitochondria per 100 μm) in the PLM axon caused by MALS-1 overexpression. …”
  4. 1104
  5. 1105
  6. 1106
  7. 1107
  8. 1108
  9. 1109
  10. 1110
  11. 1111
  12. 1112
  13. 1113
  14. 1114

    Summary map of all contacts with statistically significant SVM classifications. by Alexander P. Rockhill (6053618)

    Published 2024
    “…Yellow indicates an increase in time-frequency clusters during number trials versus inter-trial intervals while blue indicates a decrease in time-frequency clusters. …”
  15. 1115

    Raw Gel. by Techit Thavorasak (13138440)

    Published 2025
    Subjects:
  16. 1116
  17. 1117
  18. 1118
  19. 1119

    (a to g) Administration of vitamin D3 increased serum phosphorus and triglycerides. by Vidya G. Bettada (22208808)

    Published 2025
    “…Analyses of serum cholesterol, HDL and triglycerides also showed a non-significant decrease in the serum HDL level upon treatment with 125 µg/Kg vitamin D3, but a noticeable increase in the serum triglyceride level was observed with 125 µg/Kg of vitamin D3.…”
  20. 1120

    Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque mean size. by Francesca Catto (21253435)

    Published 2025
    “…However, there is only a minimal effect on decreasing plaque size. (C) Short-term-treatment with a high dose of netoglitazone reveals a significant reduction in plaque size, especially observed in the hippocampus, striatum, thalamus, hypothalamus, midbrain, and hindbrain. …”